Pfizer’s Shares Fall As It Leaves Forecast For COVID Products Unchanged

On Thursday, Pfizer Inc. reported its quarterly results but did not change the sales forecast for the year of its COVID-19 antiviral treatment and vaccine.

This saw the company’s shares record losses of 5% before they managed to trim some of them.

Pfizer report

Even though the sales of Pfizer’s Paxlovid antiviral pills for the second quarter were significantly higher than expected, the US drugmaker kept its forecast of COVID products for the full year at $54 billion.

This prompted concerns about the long-term growth prospects of the company. Wall Street estimates had put the sales of Paxlovid a full $1 billion below the actual results.

Pfizer disclosed that the second quarter sales for the antiviral treatment were $8.1 billion, as demand for the treatment rose with a rise in cases.

US President Joe Biden also recently took a course on the drug because of his bout with COVID.

The drugmaker also did not change its overall forecast and chose to keep it between $98 billion and $102 billion because of a strong dollar.

Sales performance

There has been an unprecedented increase in the sales of Pfizer Inc., after it rolled out its COVID-19 vaccine globally, which it had developed with German firm BioNTech.

However, since the previous year, there has been a decline in the sales figure. Analysts seem to be divided over the durability of the Paxlovid treatment as well as the vaccine, considering that the urgency of the pandemic is waning.

Market analysts said that the long-term sustainability of the business is debatable and it will be essential for Pfizer to develop new drugs in order for it to be able to surpass expectations.

The company has been relying on sales of the booster doses of its vaccine to boost demand in the next couple of years, including a vaccine version tailed for the Omicron variant expected in the fall.

Vaccine deal

Last month, Pfizer Inc. and BioNTech signed a deal with the US government worth $3.2 billion for about 105 million doses of the COVID-19 vaccine.

This also includes the supply of the booster that has been adapted for the Omicron variant, which is yet to get regulatory clearance.

The sales for the second quarter overall were $27.74 billion, which were higher than the estimates of $25.74 billion from analysts.

Market analysts said that if COVID is excluded from the picture, then it appears to be less rosy for the company.

This is because sales of other drugs and treatments by Pfizer, such as Xeljanz for arthritis and Ibrance for breast cancer, were well below estimates.

The numbers stood at $430 million and $1.32 billion, respectively. There was a 13% increase in the sales of the COVID-19 vaccine, which saw them reach $8.85 billion.

The second quarter profit of Pfizer Inc. climbed to $9.91 billion, as opposed to a year ago when it had been $5.56 billion. The company’s shares recorded a decline of 1.2% to trade at $50.93.

Leave a Reply

Your email address will not be published.

Related

Payback Ltd Review – Is It a Legit Scam Recovery Company?

Payback Ltd Rating 4.6 Summary Read our Payback Ltd review at FStar Capital Forex and Cryptocurrency Trading blog, find the answer to your question “is Payback Ltd scam or legit recovery company” and much more! We have checked all the aspects of this recovery firm and we recommend Payback Ltd for fund recovery. You can […]

Bitcoin has rejected $24k for Now While ETH Has Hit a 2-Month High

Bitcoin Could Not Get Past $24k   Bitcoin has reportedly ended the month of July mainly experiencing greens. The price of Bitcoin continued moving in the upward direction.  Since February of 2022, Bitcoin had not been able to climb higher at a significant rate. However, the price of Bitcoin had finally started showing signs of retracement […]

Disappointing GDP Results Cause Philippine Peso to Slip

On Tuesday, the trading price of the Philippine peso fell tremendously. Its value ended up experiencing the worst downward movement compared to the rest of the fiat currencies on Tuesday. The reason why the Philippine peso performed worse than its Asian peers was due to below-expectation GDP growth. Philippine’s GP growth was not as much […]

EUR Has Gained Momentum Against USD And It Is Currently At A Higher Ground

The trading price of the EUR/USD pair has improved tremendously in recent trading sessions. The data suggests that it is currently trading near the 1.0200 benchmarks. Euro Gains Momentum after Posting Eurozone Sentix Data The data surrounding the Eurozone Sentix was recently posted, showing that it has improved in the month of August. A downtrend […]

Optimism (OP) Rallied by Almost 300% in 30-Days, Will its Rally Sustain?

The trading value of Optimism (OP) has been undergoing significant growth in the past 30-days. Since the start of July, the trading value of Optimism has continued surging, which is due to its connection with Ethereum. Almost 300% Rally Recorded by Optimism The trading price of Optimism has experienced an almost 300% rally in the […]